GAMIDA CELL LTD.

Analyst Reco. Gamida Cell Ltd.

Equities

GMDA

IL0011552663

Market Closed - OTC Markets Other stock markets 03:53:27 2024-05-23 pm EDT			5-day change	1st Jan Change
0.0166 ^USD	+2.47%		+0.61%	-95.98%

May. 23	Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 10	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform	Jan. 29	MT
Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating	Nov. 15	MT
HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating	Nov. 15	MT
JMP Securities Adjusts Price Target on Gamida Cell to $6 From $8, Keeps Market Outperform Rating	23-05-19	MT
Oppenheimer Adjusts Gamida Cell Price Target to $6 From $8, Maintains Outperform Rating	23-05-16	MT
Needham Lowers Price Target on Gamida Cell to $6 From $8, Maintains Buy Rating	23-04-20	MT
HC Wainwright Adjusts Price Target on Gamida Cell to $11 From $5, Keeps Buy Rating	23-04-19	MT
Oppenheimer Adjusts Gamida Cell Price Target to $8 From $10, Maintains Outperform Rating	23-03-28	MT
HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $22, Maintains Buy Rating	23-03-28	MT
Needham Adjusts Price Target on Gamida Cell to $8 From $9, Maintains Buy Rating	22-11-22	MT
Oppenheimer Adjusts Gamida Cell PT to $10 From $15, Notes Uncertainty Around Ex-US Regulatory, Commercial Strategy; Maintains Outperform Rating	22-11-15	MT
Piper Sandler Adjusts Gamida Cell's Price Target to $7 From $8, Reiterates Overweight Rating	22-10-03	MT
Needham Adjusts Price Target on Gamida Cell to $12 from $14, Keeps Buy Rating	21-11-16	MT
Oppenheimer Adjusts Gamida Cell PT to $15 From $17, Maintains Outperform Rating	21-11-16	MT
RBC Cuts Price Target on Gamida Cell to $11 From $14, Citing Setback to Omidubicel Filing Timeline; Outperform-Speculative Risk Rating Kept	21-11-12	MT
GAMIDA CELL : RBC Capital Adjusts Gamida Cell PT to $14 From $12, Maintains Outperform - Speculative Risk	21-03-10	MT
GAMIDA CELL : Needham Adjusts Price Target on Gamida Cell to $14 From $17, Maintains Buy Rating	21-03-09	MT
GAMIDA CELL : Oppenheimer Adjusts Gamida Cell PT to $17 From $20, Maintains Outperform Rating	20-12-15	MT
GAMIDA CELL : RBC Capital Adjusts Gamida Cell's Price Target to $12 From $13, Maintains Outperform-Speculative Risk Rating	20-12-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer